Abiword HTML Document
AcelRx Pharmaceuticals'( ACRX) DSUVIA (sufentanil sublingual tablet) went under intense scrutiny by the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee (adcom) on Friday. After a long day of presentations and debate, the committee gave a 10-3 vote for recommending FDA approval. Trade was halted throughout the day because of the adcom event, but was unhalted at 4:45 PM EST. Once trading resume, the share price rocketed to $5.00 and ended the day at $4.92.
ACRX has had a volatile week with the briefing document debacle, recovery, and FDA